Fast dissolving pharmaceutical composition
AssigneeFerring B.V.
InventorsVarinder Ahuja, Tejas Gunjikar, Kristin Wannerberger
Life of this patent
Estimating the term…
Abstract
The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises inulin.
Claims38
A pharmaceutical composition comprising:
- (a) at least one matrix-forming agent that is inulin to form an open matrix network, wherein the inulin ranges from 30% to 80% of the entire weight of the composition;
- and
- (b) at least one pharmaceutically active ingredient chosen from desmopressin, desmopressin acetate, loratidine, famotidine, montelukast sodium, and ondansetron HCl carried by the open matrix network,
- wherein at least 80% of the pharmaceutical composition dissolves within 10 seconds upon contact with an aqueous solution.
A pharmaceutical composition prepared by a process comprising at least a step of sublimating a solvent from a liquid preparation that comprises:
- (a) at least one matrix forming agent that is inulin, wherein the inulin ranges from 30% to 80% of the entire weight of the composition;
- and
- (b) at least one pharmaceutically active ingredient chosen from desmopressin, desmopressin acetate, loratidine, famotidine, montelukast sodium, and ondansetron HCl.
A pharmaceutical composition comprising:
- (a) a first matrix forming agent that is inulin, wherein the inulin ranges from 30% to 80% of the entire weight of the composition and, optionally, a second matrix forming agent selected from the group consisting of trehalose, raffinose, and mannitol, to form an open matrix network;
- and
- (b) at least one pharmaceutically active ingredient chosen from desmopressin, desmopressin acetate, loratidine, famotidine, montelukast sodium, and ondansetron HCl carried by the open matrix network,
- wherein at least 80% of the pharmaceutical composition dissolves within 10 seconds upon contact with an aqueous solution.
A blister pack having one or more depressions disposed therein, wherein each of the one or more depressions comprises a pharmaceutical composition, the pharmaceutical composition comprises:
- (a) at least one matrix-forming agent that is inulin to form an open matrix network;
- and
- (b) at least one pharmaceutically active ingredient chosen from desmopressin, desmopressin acetate, loratidine, famotidine, montelukast sodium, and ondansetron HCl carried by the open matrix network.
Dependencies are inferred from the claim text.